Nancy Whiting
Director/Board Member chez CARIBOU BIOSCIENCES, INC.
Fortune : - $ au 31/03/2024
Postes actifs de Nancy Whiting
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/08/2021 | - |
| Independent Dir/Board Member | 24/08/2021 | - | |
| BOUNDLESS BIO, INC. | Director/Board Member | 02/10/2023 | - |
| Independent Dir/Board Member | 02/10/2023 | - | |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Director/Board Member | 01/09/2021 | - |
| Chief Executive Officer | 01/09/2021 | - |
Historique de carrière de Nancy Whiting
Anciens postes connus de Nancy Whiting
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | Director/Board Member | - | - |
| President | 09/03/2018 | - | |
| Corporate Secretary | 09/03/2018 | - | |
| SEAGEN INC. | Public Communications Contact | - | - |
Formation de Nancy Whiting
| University of Washington | Graduate Degree |
| University of British Columbia | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Canada | 2 |
| 2 |
Opérationnelle
| Director/Board Member | 4 |
| Independent Dir/Board Member | 2 |
| Public Communications Contact | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
| Boundless Bio, Inc. | |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
- Bourse
- Insiders
- Nancy Whiting
- Expérience
